Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. 薬物名（臨床試験情報から抽出） DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY 指定難病告示番号
114C]-RPC1063 Solution (0.1 mg/mL) for Oral Administration----3件: 13, 96, 97
2ADMINISTRATION----1件: 19
3Administration Kit----1件: 19
4Administration of a high dose of desipramine1件: Desipramine2件: D00812 ,
D07791 		2件: SLC6A2,
SLC6A4 💬		2件: Serotonergic synapse, Synaptic vesicle cycle 💬1件: 156
5Administration of a low dose of desipramine1件: Desipramine2件: D00812 ,
D07791 		2件: SLC6A2,
SLC6A4 💬		2件: Serotonergic synapse, Synaptic vesicle cycle 💬1件: 156
6Administration of an ACE-inhibitor or not----1件: 210
7Administration of Cimzia®1件: Certolizumab pegol1件: D03441 1件: TNF 💬67件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬1件: 46
8Administration of drug (Interferon-gamma 1-b) subcutaneously----1件: 65
9Administration of Methylprednisolone + Prednisone + Mycophenolate mofetil4件: Methylprednisolone,
Mycophenolate mofetil,
Mycophenolic acid,
Prednisone		11件: D00407 ,
D00473 ,
D00751 ,
D00752 ,
D00979 ,
D05000 ,
D05001 ,
D05002 ,
D05094 ,
D05095 ,
D05096 		3件: IMPDH1,
IMPDH2,
NR3C1 💬		4件: Drug metabolism - other enzymes, Metabolic pathways, Neuroactive ligand-receptor interaction, Purine metabolism 💬1件: 49
10Administration of methylprednisolone, paracetamol and dexchlorpheniramine3件: Acetaminophen,
Dexchlorpheniramine,
Methylprednisolone		8件: D00217 ,
D00407 ,
D00751 ,
D00979 ,
D05000 ,
D05001 ,
D05002 ,
D07803 		4件: HRH1,
NR3C1,
PTGS1,
PTGS2 💬		26件: Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Calcium signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Inflammatory mediator regulation of TRP channels, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Neuroactive ligand-receptor interaction, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬1件: 49
11Administration of rituximab and methylprednisolone2件: Methylprednisolone,
Rituximab		7件: D00407 ,
D00751 ,
D00979 ,
D02994 ,
D05000 ,
D05001 ,
D05002 		2件: MS4A1,
NR3C1 💬		2件: Hematopoietic cell lineage, Neuroactive ligand-receptor interaction 💬1件: 51
12Administration of stable isotope-labelled leucine-1件: Leucine1件: D00030 --1件: 6
13Avandia administration for 6-12 weeks----1件: 265
14Behavioral: Administration of probiotic (L. rhamnosus and L. acidophilus)1件: Lactobacillus acidophilus1件: D04349 --1件: 97
15Biological : I10E (Human normal Immunoglobulin for intravenous administration 100mg/mL)1件: Human immunoglobulin G---1件: 14
16Biological: Kiovig® (Human normal Immunoglobulin for intravenous administration 100mg/mL)1件: Human immunoglobulin G---1件: 14
17Bosentan administration1件: Bosentan2件: D01227 ,
D07538 		2件: EDNRA,
EDNRB 💬		9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 86
18CS1 Administration----1件: 86
19Docosahexaenoic acid administration: 50 mg/kg/day during 12 months1件: Doconexent---1件: 299
20Experimental: CRH administration----2件: 72, 78
21Experimental: GLP1-RA (exenatide) administration1件: Exenatide1件: D04121 1件: GLP1R 💬3件: Insulin secretion, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬2件: 72, 78
22Growth hormone administration for 6 months1件: Somatotropin1件: D02691 1件: GHR 💬5件: Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway 💬1件: 78
23Human normal 10% immunoglobulin for intravenous administration1件: Human immunoglobulin G---1件: 14
24Human normal 10% immunoglobulin for intravenous administrationn1件: Human immunoglobulin G---1件: 14
25Human normal immunoglobulin for intravenous (IV) administration1件: Human immunoglobulin G---1件: 51
26Human normal immunoglobulin for intravenous administration1件: Human immunoglobulin G---3件: 14, 51, 65
27Human normal immunoglobulin for subcutaneous administration1件: Human immunoglobulin G---2件: 51, 65
28Human Normal Immunoglobulin for Subcutaneous Administration (IGSC)1件: Human immunoglobulin G---1件: 65
29Intrathecal administration of autologous MSC-NP----1件: 13
30Intravenous administration of 1 million of MSC----1件: 2
31Intravenous administration of 2 million of MSC----1件: 2
32Intravenous administration of 4 million of MSC----1件: 2
33Intravenous administration of ferric carboxymaltose1件: Ferric carboxymaltose1件: D08920 --1件: 86
34IV administration of Genetically Engineered Hematopoietic Stem/Progenitors Cells (HSPCs)----1件: 285
35Levodopa (drug), intraduodenal administration1件: Levodopa1件: D00059 5件: DRD1,
DRD2,
DRD3,
DRD4,
DRD5 💬		11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 6
36Levodopa and carbidopa solution for SC administration2件: Carbidopa,
Levodopa		2件: D00059 ,
D00558 		6件: DDC,
DRD1,
DRD2,
DRD3,
DRD4,
DRD5 💬		16件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬1件: 6
37Low-dose IL-2 administration1件: Human interleukin-2---1件: 96
38Methotrexate + biologic administration1件: Methotrexate2件: D00142 ,
D02115 		2件: DHFR,
DHFR2 💬		5件: Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬1件: 46
39Methotrexate + salazopyrine + hydroxychloroquine administration2件: Hydroxychloroquine,
Methotrexate		3件: D00142 ,
D02115 ,
D08050 		2件: DHFR,
DHFR2 💬		5件: Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬1件: 46
40Methotrexate(MTX) administration is at the discretion of the rheumatologist and no tradename is fixed by the protocol1件: Methotrexate2件: D00142 ,
D02115 		2件: DHFR,
DHFR2 💬		5件: Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬1件: 46
41Methotrexate(MTX) administration is at the discretion of the rheumatologist and no tradename is fixed by the protocol.1件: Methotrexate2件: D00142 ,
D02115 		2件: DHFR,
DHFR2 💬		5件: Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬1件: 46
42NIRS after bosentan administration1件: Bosentan2件: D01227 ,
D07538 		2件: EDNRA,
EDNRB 💬		9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 13
43Obinutuzumab administration1件: Obinutuzumab1件: D09321 1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 49
44Other: Questionnaire Administration----4件: 16, 34, 51, 298
45Other: Tobramycin time of administration1件: Tobramycin2件: D00063 ,
D02542 		--1件: 299
46QR-313 Gel for Topical (Cutaneous) Administration----1件: 36
47RAAV1-CMV-GAA (study agent) Administration----1件: 256
48Routine steroid administration group----1件: 85
49Semi continuous intra-oral administration of LD/CD----1件: 6
50Subcutanious administration----1件: 46
51Subretinal administration of rAAV2-VMD2-hMERTKRecombinant Adeno-Associated Virus----1件: 90
52TCD after bosentan administration1件: Bosentan2件: D01227 ,
D07538 		2件: EDNRA,
EDNRB 💬		9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 13